NOXOPHARM LIMITED

0.00%

10.0¢

Market Cap $29.22M

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel... Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.More

Latest Threads

Tag

Subject

NOX

Ann: Appendix 4E Preliminary Final Report

29/08/25

131

29/08/25

Last post

ASX News

131

NOX

Ann: Sofra technology platform presentation

28/08/25

808

28/08/25

Last post 19661966

808

NOX

Ann: HERACLES clinical trial Update 3

27/08/25

1.2K

27/08/25

Last post 3H

1.2K

NOX

Ann: HERACLES clinical trial Update 2

12/08/25

1.7K

12/08/25

Last post 19661966

1.7K

NOX

Ann: US company demonstrates strong Sofra potential

07/08/25

2.2K

07/08/25

Last post 19661966

2.2K

NOX

Ann: June 2025 Quarterly Activities Report and Appendix 4C

04/08/25

1.5K

04/08/25

Last post Bendunstan

1.5K

NOX

Ann: HERACLES clinical trial - Update 1

29/07/25

2.5K

29/07/25

Last post Pierzzxx

2.5K

NOX

Ann: First SOF-SKN dose in HERACLES clinical trial

21/07/25

1.9K

21/07/25

Last post 19661966

1.9K

See All Discussions

Timeline

Appendix 4E Preliminary Final Report
29 Aug 08:08	Share

Sofra technology platform presentation
28 Aug 08:58	Share

HERACLES clinical trial Update 3
25 Aug 09:30	Share

HERACLES clinical trial Update 2
11 Aug 08:31	Share

US company demonstrates strong Sofra potential
05 Aug 08:28	Share

June 2025 Quarterly Activities Report and Appendix 4C
30 Jul 08:30	Share

HERACLES clinical trial - Update 1
28 Jul 09:39	Share

First SOF-SKN dose in HERACLES clinical trial
16 Jul 08:14	Share

Clinical trial recruitment progressing rapidly
25 Jun 10:08	Share

Promising Sofra results from overseas company
11 Jun 11:11	Share

Green light for HERACLES clinical trial
29 May 08:37	Share

NYR: Notice of Ceasing to be a Substantial Holder - NOX
21 May 08:21	Share

Notice of Change of Interests of Substantial Holder for NYR
20 May 09:29	Share

NYR: Corporate Update
20 May 09:20	Share

New funds from Nyrada share sales
20 May 08:48	Share

SOF-SKN data presented at rheumatology conference
06 May 08:24	Share

Noxopharm clinical trial submission
02 May 08:45	Share

March 2025 Quarterly Activities Report and Appendix 4C
30 Apr 08:55	Share

SOF-SKN successfully passes final pre-trial study
15 Apr 08:22	Share

Noxopharm expands collaboration with Hudson Institute
25 Mar 08:49	Share

Doherty Clinical Trials to host HERACLES trial
12 Mar 10:10	Share

Appendix 4D and FY2025 Half Year Financial Report
25 Feb 13:38	Share

SOF-SKN passes required in vitro safety tests
04 Feb 08:17	Share

December 2024 Quarterly Activities Report and Appendix 4C
29 Jan 08:17	Share

Notice under s708A(12C)(e) of the Corporations Act 2001
10 Jan 16:29	Share

Notification regarding unquoted securities - NOX
10 Jan 16:25	Share

Notification regarding unquoted securities - NOX
10 Jan 16:22	Share

Convertible Note update
18 Dec 15:01	Share

Change of Director's Interest Notice - BP
16 Dec 08:33	Share

Notification of cessation of securities - NOX
16 Dec 08:22	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 10.0¢		Change 0.000(0.00%)		Mkt cap ! $29.22M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	59622	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	61000	3

View Market Depth

No.	Vol.	Price($)
2	59622	0.100
1	50700	0.097
1	186361	0.096
1	11111	0.090
1	10000	0.080

Price($)	Vol.	No.
0.110	61000	3
0.115	55816	3
0.120	15100	2
0.130	5500	1
0.135	49390	2

Last trade - 16.21pm 03/09/2025 (20 minute delay)


Last 10.0¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
10.0¢	10.0¢	10.0¢	6303
Last updated 14.05pm 03/09/2025 ?

NOX (ASX) Chart

NOXOPHARM LIMITED

Latest Threads

Listen: HotCopper Wire Podcast 023 – Glowing gold, shining silver, and... wheat collusion?

Timeline

Featured News

Latest Videos

Noxopharm (ASX:NOX) receives green light to progress DARRT-2 trial

17 Jan 2023 10:35 (AEDT)

Latest Articles

Noxopharm gets HERACLES autoimmune trials started with first human doses

Noxopharm Ltd (ASX:NOX) has got its HERACLES trials out the gates in Week 29, dosing a preliminary patient in the first-in-human use of its SOF-SKN topical drug candidate targeting TLR7/8 for autoimmune diseases.Listen to the HotCopper podcast for in-depth discussions and insights on all the bigg...

Noxopharm jumps as flagship lupus drug clears first-pass in vitro safety tests

Noxopharm has reported its lupus medication in development, SOF-SKN, has passed first-stage in vitro safety tests before clinical trials.

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Noxopharm Ltd is planning the first human trial to assess novel drug SOF-SKN, which aims to treat autoimmune conditions.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News